A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation

NCT05776108 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Cabotegravir IR Formulation (reference)
DRUG: Cabotegravir DT Formulation (test 1)
DRUG: Cabotegravir DT Formulation (test 2)

Sponsor

ViiV Healthcare